Clinical Observation Of Qianlong Yigan Prescription In The Treatment Of Liver Cirrhosis Compensation Period(Liver-kidney Yin Deficiency Syndrome)

Objective: To observe the effects of Qianlong Yigan Prescription on liver function index,liver fiber four items,liver hardness value,ultrasound index of liver biliary,spleen,pancreas and portal system and quantitative score of TCM syndrome grading in patients with hepatitis B cirrhosis during compensatory period(liver-kidney Yin deficiency syndrome)and evaluate its clinical efficacy and safety.Methods: In this study,60 patients with hepatitis B cirrhosis during the compensatory period(liver-kidney Yin deficiency syndrome)meeting the inclusion criteria were collected and divided into treatment group(30 cases)and control group(30 cases)by random number table method.The control group was given routine medical treatment,and the treatment group was combined with Qianlong Yigan prescription on the basis of routine medical treatment for 6 months(a total of 24 weeks).Liver function and liver fiber four items were recorded in the two groups at week 0,week 12 and week 24,and the changes of ultrasound of liver,bile,spleen and pancreas,portal vein system(spleen thickness,portal vein main diameter,portal vein velocity),liver hardness measurement,and index of TCM symptoms were recorded in week 0 and week 24.The patients’ blood,urine and stool routine,renal function and electrocardiogram before and after treatment were monitored,and adverse reactions occurred during the course of treatment were recorded.The data results were statistically processed and analyzed by SPASS 26.0software.Results:(1)Overall efficacy: After 24 weeks of treatment,there were 0 cases of obvious effect,17 cases of effective cases and 13 cases of ineffective cases in the control group,and the total effective rate was 56.67%.In the treatment group,there were 17 cases of obvious effect,7 cases of effective,6 cases of ineffective,and the total effective rate was 80.00%.There was statistical significance in the overall efficacy evaluation between the two groups(P <0.05).(2)TCM syndrome scores evaluation: After 24 weeks of treatment,TCM syndrome scores in both groups were improved,and the decline of the treatment group was better than that of the control group,the difference between the two was statistically significant(P < 0.05).(3)Liver function indexes: there was no significant difference in the values of ALT,AST and TBIL between the two groups before treatment(P >0.05);After 12 and 24 weeks of treatment,the indexes of ALT and AST decreased in 2 groups,and the differences were statistically significant between the two groups(P < 0.05),indicating that the improvement of the treatment group was better than that of the control group.After 12 weeks of treatment,the TBIL value of the two groups was decreased,and the difference was statistically significant between the two groups(P < 0.05).After 24 weeks of treatment,TBIL in both groups decreased compared with before,with statistical significance in intra-group comparison(P < 0.05),but no statistical significance in inter-group comparison(P > 0.05).(4)Liver fiber four items and liver hardness index: After 12 and 24 weeks of treatment,liver fibr(HA,LN,CIV,PⅢP)in 2 groups were decreased compared with before treatment(P < 0.05),and the decreased levels of HA,LN,CIV and PⅢP in treatment group were better than those in control group(P < 0.05).(5)Ultrasound indexes of liver,bile,spleen,pancreas and portal vein system: After 24 weeks of treatment,spleen thickness,portal vein diameter and portal vein flow velocity were improved in 2 groups,and the differences were statistically significant(P < 0.05).After 24 weeks of treatment,there was no significant difference in spleen thickness,portal vein diameter and portal vein flow rate between the two groups(P > 0.05).(6)Safety observation: During the clinical study,no obvious abnormalities were detected in the safety indexes of the two groups of patients,and no adverse reactions or toxic side effects occurred.Conclusion: Qianlong Yigan Prescription can effectively improve the clinical symptoms,signs,liver function,liver fibrosis,liver hardness and other indicators of patients with hepatitis B cirrhosis during the compensatory period(liver-kidney Yin deficiency syndrome).It has the effect of reducing the degree of liver fibrosis and assisting to improve liver function,with definite clinical efficacy and high drug safety coefficient.